TD Cowen analyst Steven Mah reiterated a Buy rating on AbCellera Biologics (ABCL – Research Report) yesterday. The company’s shares closed yesterday at $4.43.
According to TipRanks, Mah is an analyst with an average return of -18.9% and a 20.56% success rate. Mah covers the Healthcare sector, focusing on stocks such as BioLife Solutions, AbCellera Biologics, and Ginkgo Bioworks Holdings.
Currently, the analyst consensus on AbCellera Biologics is a Strong Buy with an average price target of $22.50.
See Insiders’ Hot Stocks on TipRanks >>
Based on AbCellera Biologics’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $10.06 thousand and a GAAP net loss of $30.53 thousand. In comparison, last year the company earned a revenue of $45.92 thousand and had a GAAP net loss of $6.79 thousand
Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ABCL in relation to earlier this year. Most recently, in August 2023, Hansen Carl L. G., the CEO of ABCL bought 56,125.00 shares for a total of $151,537.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AbCellera Biologics (ABCL) Company Description:
AbCellera Biologics Inc is a biotechnology company. The company develops antibodies to treat highly infectious diseases and various other types of diseases.
Read More on ABCL:
